You are viewing the site in preview mode
Skip to main content
| |
Eta was not withdrawn by inactive disease, n = 1392
|
Eta was withdrawn by inactive disease, n = 332
|
HR
|
p value
|
95% CI
|
|---|
|
Female gender
|
945 (67.9%)
|
201 (60.5%)
|
0.96
|
0.749
|
0.73 to 1.25
|
|
Age, years, mean (SD)
|
13.7 (3.5)
|
11.9 (3.1)
|
0.92
|
< 0.001
|
0.89 to 0.96
|
|
ANA positive
|
589 (42.5%)
|
128 (38.7%)
|
0.82
|
0.148
|
0.62 to 1.07
|
|
HLA-B27 positive
|
368 (26.6%)
|
104 (31.4%)
|
1.10
|
0.57
|
0.78 to 1.55
|
|
JIA categories
|
|
Systemic JIA
|
96 (6.9%)
|
15 (4.5%)
|
0.83
|
0.512
|
0.47 to 1.45
|
|
Polyarticular arthritis, RF-negative
|
386 (27.7%)
|
101 (30.4%)
|
1.08
|
0.572
|
0.83 to 1.39
|
|
Polyarticular arthritis RF-positive
|
156 (11.2%)
|
20 (6.0%)
|
0.56
|
0.014
|
0.35 to 0.89
|
|
Persistent Oligoarthritis
|
48 (3.5%)
|
25 (7.5%)
|
1.89
|
0.004
|
1.22 to 2.93
|
|
Extended Oligoarthritis
|
247 (17.7%)
|
60 (18.1%)
|
1.08
|
0.648
|
0.79 to 1.47
|
|
Enthesitis-related arthritis
|
286 (20.6%)
|
73 (22.0%)
|
1.24
|
0.197
|
0.89 to 1.71
|
|
Psoriatic arthritis
|
126 (9.1%)
|
22 (6.6%)
|
0.89
|
0.582
|
0.59 to 1.35
|
|
Duration between JIA onset and bDMARD start, in months, mean (SD)
|
60.8 (48.5)
|
46.0 (38.3)
|
0.91
|
< 0.001
|
0.87 to 0.95
|
|
c-JADAS-10
|
|
At therapy start
|
15.1 (6.7)
|
14.5 (6.5)
|
0.9
|
< 0.001
|
0.86 to 0.93
|
|
Therapy response within the first 6 months
|
9.3 (6.6)
|
11.3 (6.6)
|
1.12
|
< 0.001
|
1.07 to 1.16
|
- ANA antinuclear antibodies, bDMARD biological disease-modifying anti-rheumatic drug, CI confidence interval, cJADAS clinical Juvenile Arthritis Disease Activity Score, HLA human leukocyte antigen, HR hazard ration, RF rheumatoid factor, SD standard deviation
